The Board of Directors collaborates to provide strategic clarity, direction, and policy objectives for DIA. The Board of Directors and its Standing Committees ensure DIA meets the requirements of our members in the content of our programs, research, and financial decisions.

Board membership is voluntary, and DIA does not compensate Directors or members of Advisory Councils for their contributions.

Judith Ng-Cashin

Chair of DIA Board

Chair of Executive Committee

  
Judith Ng-Cashin, MD, former Chief Medical Officer at Eagle Pharmaceuticals, leading R&D across the development pipeline and marketed products. Prior to this role, she served as CMO for AOBiome Therapeutics, leading end-to-end asset development strategy, medical governance, and manufacturing. She also served as Chief Scientific Officer and led the Safety & Pharmacovigilance business unit for Syneos Health. Before Syneos, she spent nearly a decade in R&D for a top five pharmaceutical company. Dr. Ng-Cashin earned her MD from Rush Medical College, trained in Internal Medicine at the University of Chicago, and received an infectious diseases and hematology fellowship training at the University of North Carolina.

Lingshi Tan

Immediate Past Chair

Chair of Governance Committee

  
Dr. Lingshi Tan is Chairman and CEO of dMed-Clinipace, a Global full-service Clinical CRO that aspires to be a next-generation clinical development partner empowering customers to deliver innovative solutions to patients worldwide, especially in the U.S. and China. dMed-Clinipace is resulted in a merger between dMed and Clinipace in April 2021. Prior to founding dMed in 2016, Dr. Tan was Pfizer’s VP of Worldwide Development Operations and Chairman and GM of Pfizer (China) Research & Development Co., Ltd. (CRDC). Dr. Tan was assigned from New York to Shanghai to establish the CRDC in 2005. Under his leadership for 11 years, the CRDC grew to an organization of over 1,000 professionals and became an integral part of Pfizer’s global R&D network

Cynthia L. Verst

Chair-Elect

  
Dr. Cynthia Verst is President, Design and Delivery Innovation, Research & Development Solutions at IQVIA. Having previously served as president of both Clinical Operations and Real World and Late Phase Research for IQVIA, Dr. Verst brings a holistic view of clinical research, and champions the advanced use of real-world data, analytics, and technology to advance therapies for patients. Prior to joining IQVIA (then Quintiles), she served as SVP, Global Late Phase Research for OptumInsight. Dr. Verst holds a doctorate and a bachelor’s degree in Pharmacy from the Univ. of Cincinnati, a master’s degree in Structural and Cellular Biology from the Univ. of Illinois, and bachelor’s degrees in Biology and Chemistry from Northern Kentucky Univ.

Michael Romano

Secretary/Treasurer

Chair of Finance Committee

  
Michael Romano is a Partner and leader of the Life Sciences Industry practice group for RSM US LLP; he is also a Partner in RRSM’s Managed Technology Services Practice, and leads RSM’s Finance and Accounting Outsourcing group. Michael has more than 25 years of diverse experience in both the life sciences industry and as an audit and business consultant, and has orchestrated successful financial and operational turnarounds, restructured and reorganized businesses, and successfully executed growth strategies in the life sciences industry. He also served as Vice President and General Manager of a global medical publisher offering health information products and services to the pharmaceutical, biotech, and medical device markets.

Barbara Lopez Kunz

President and Global Chief Executive

  
Barbara Lopez Kunz serves as President and Global Chief Executive of DIA, driving thought leadership and innovation in therapeutic development to improve the health of people worldwide. She previously served as President of Health and Life Sciences at Battelle, one of the world’s largest, most respected R&D organizations. She has also served as Senior Vice President/General Manager for Thermo Fisher Scientific’s Biosciences Division, as SVP for DuPont, and head of R&D for ICI. A dedicated volunteer for children's health, Barbara chairs the board of Children's National Research Institute, serves as advisor to the UC I4H Fellowship, and as Director for Aptevo Therapeutics.

Mike A. B. Devoy

Director

  
Dr Michael Devoy is the Executive Vice President for Medical Affairs and Pharmacovigilance for the Pharmaceuticals Division at Bayer AG. He is also the Chief Medical Officer of Bayer AG. Dr Devoy joined the former Schering AG in 2005 as Senior VP of Global Medical Development and was appointed to his current position in 2014. Dr Devoy studied Medicine and Pharmacology at University College London and graduated with a Bachelor of Medicine/Bachelor of Surgery (MB, BS). He is a member of the Royal College of Physicians in London. Dr Devoy has extensive experience across Clinical Development and International Medical Affairs. His career in the pharmaceutical industry began when he joined Glaxo Group Research in Clinical Pharmacology.

Peter Honig

Director

  
Dr. Honig is former SVP and Head of Global Regulatory Affairs and Group Head of Development for China and Japan, overseeing regulatory effectiveness, quality control and compliance at Pfizer. Prior to joining Pfizer, he held senior leadership positions at AstraZeneca, Merck Research Laboratories and the FDA, which includes being the first Director of the Office of Drug Safety in the FDA’s Center for Drug Evaluation and Research (CDER). In addition to his industry and FDA experience, Dr. Honig was the PhRMA representative to the ICH Steering Committee from 2002 to 2021 and is a past President of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). Dr. Honig received his BA, MD, and MPH from Columbia University.

Frank N. Jiang

Director

  
Frank Jiang, MD, Ph.D., is Chief Executive Officer and Chairman of the Board of CStone Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development of innovative oncology drugs. Prior to joining CStone Pharmaceuticals, Dr Jiang served as Head of Asia Pacific R&D with Sanofi and built a R&D regional hub encompassing Japan, China and among other 12 countries with 1,400 staff. One of his career highlights at Sanofi was leading a 21,000 patient ‘megatrial’, which resulted in a successful global registration of a blockbuster drug Lovenox. Prior to Sanofi, Dr Jiang served as clinical research physician with Eli Lilly and led a global phase II trial in Sepsis. Dr Jiang is a US board certified physician (internal medicine)

Tatyana Kosheleva

Director

Chair of Audit Committee

  
Tatyana Kosheleva, CPA, is currently CFO at Amring Pharmaceuticals Inc. where she is a member of the Executive Board responsible for all aspects of the firm's financial operations. Tatyana has over 20 years of diverse Finance experience ranging from start-ups to Fortune 50 public companies in the life sciences and technology industries across four countries. Tatyana earned her MBA degree in International Management from Thunderbird School of Global Management, a part of the Arizona State University.

Michael Rosenblatt

Director

  
Michael Rosenblatt, MD, Senor Partner at Flagship Pioneering, has advanced academic and biopharmaceutical research and development throughout his career. He was previously Chief Medical Officer for Merck, after serving as Dean of Tufts Medical School. Formerly, he was Ebert Professor of Molecular Medicine and Minot Professor at Harvard. He served as President of Beth Israel Deaconess Medical Center and as Director of the Harvard-MIT Division of Health Sciences & Technology. He is on the board of several life sciences companies, and on the Harvard Medical School Board of Fellows and research advisory committees of the Massachusetts General, Brigham and Women’s, and Boston Children’s Hospitals. He earned his MD from Harvard Medical School.

Peter Sorger

Director

  
Peter Sorger is the Otto Krayer Professor of Systems Pharmacology at Harvard Medical School. He received his AB from Harvard College and PhD from Trinity College, Cambridge University U.K., working under the supervision of Hugh Pelham. He trained as a postdoctoral fellow at the University of California, San Francisco with Harold Varmus and Andrew Murray. Prior to coming to HMS Peter served as a Professor of Biology and Biological Engineering at MIT. Sorger was cofounder of Merrimack Pharmaceuticals and Glencoe Software and is an advisor to multiple public and private companies and research institutes in the US, Europe and Japan.

Kihito Takahashi

Director

  
Dr. Takahashi is currently Director and Chief Operating Officer, BONAC Corporation, a bio-tech venture company in Japan. He graduated from Hokkaido University School of Medicine in 1981, and received his PhD in Medical Science in 1986. He served as Research Assistant Professor of Medicine at Vanderbilt University from 1990 to 1992, and joined Merck Research Laboratories in 1992 and served as Vice President, Merck Research Laboratories from 2003 to 2008. After retiring from Merck, he served as a President & CEO of LOTUS Pharmaceutical Co. Ltd, a bio-venture company. He joined GlaxoSmithKline in 2009 and served as Vice President and Director of Japan Development of GSK Japan before joining BONAC in January 2021.

Karin Van Baelen

Director

  
Karin is leading the Global Regulatory Affairs organization at Janssen. She facilitates the relationship between the Janssen pharmaceutical companies and global health authorities, influencing and interpreting global regulatory requirements and enabling our companies to meet those guidelines. In addition, she oversees the development of regulatory strategy for products from all therapeutic areas. Karin engages in policy development at national and international levels.

Rachel Zhang

Observer

  
Rachel has over two decades of healthcare consulting and life science management experiences. Formerly a partner in McKinsey & Company’s New York Office, Rachel oversaw the design and delivery of corporate and R&D transformation programs, working with leading pharmaceutical companies as well as global health non-profit organizations. In 2016 she founded New Path Global LLC, to strengthen collaboration across academia, industry, and funders, towards long-term patient and society benefits. Rachel started her career as a drug discovery biochemist with Merck Research Laboratories in West Point, Pennsylvania. She also obtained an MBA from The Wharton School